arimoclomol Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Arimoclomol is an experimental drug developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. In 2011 the worldwide rights to arimoclomol were bought by Danish biotech company Orphazyme ApS. The European Medicines Agency (EMA) and U.S. Food & Drug Administration (FDA) granted orphan drug designation to arimoclomol as a potential treatment for Niemann-Pick type C in 2014 and 2015 respectively.   Wikipedia

Chemistry

  • SMILES: O[C@@H](CO\N=C(/Cl)\c1ccc[n+]([O-])c1)CN2CCCCC2
  • InChIKey: SGEIEGAXKLMUIZ-XUVDNFPMSA-N
  • Mol. Mass: 313.79
  • ALogP: 1.08
  • ChEMBL Molecule:
    arimoclomol  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

arimoclomol | brx220 | brx-220

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Amyotrophic Lateral Sclerosis (Phase 3)

Gaucher Disease (Phase 2)

Myositis, Inclusion Body (Phase 3)

Niemann-Pick Diseases ()

Niemann-Pick Disease, Type C (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue